cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Revuforj (revumenib) • leucovorin calcium • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

PEPN1812: Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)

P1, N=16, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Dec 2026

1 day ago

Trial completion date

cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia (clinicaltrials.gov)

P3, N=556, Recruiting, Children's Oncology Group | Not yet recruiting --> Recruiting

8 days ago

Enrollment open

cytarabine • Starasid (cytarabine ocfosfate)

NCI-2021-10020: Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane (clinicaltrials.gov)

P1, N=8, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: May 2026 --> May 2027

8 days ago

Trial completion date

SELL (Selectin L)

cytarabine • leucovorin calcium • fludarabine IV • uproleselan (APL-106) • Starasid (cytarabine ocfosfate)

Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia (clinicaltrials.gov)

P1/2, N=53, Active, not recruiting, University of Southern California | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Jun 2026 --> Dec 2026

9 days ago

Trial completion date • Trial primary completion date

cytarabine • idarubicin hydrochloride • pevonedistat (MLN4924) • Starasid (cytarabine ocfosfate)

12d

Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)

P1, N=2, Terminated, Northwestern University | Active, not recruiting --> Terminated; Low accrual

12 days ago

Trial termination

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)

IDH1 R132

cytarabine • Tibsovo (ivosidenib) • idarubicin hydrochloride • fludarabine IV • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate)

13d

AALL1131: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (clinicaltrials.gov)

P3, N=5949, Completed, National Cancer Institute (NCI) | Trial completion date: Oct 2026 --> Mar 2026 | Active, not recruiting --> Completed

13 days ago

Trial completion • Trial completion date

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6)

MLL rearrangement

dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

13d

NCI-2021-09185: Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P1, N=24, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027

13 days ago

Enrollment closed • Trial completion date • Trial primary completion date

Venclexta (venetoclax) • cytarabine • cyclophosphamide • methotrexate • vincristine • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • Starasid (cytarabine ocfosfate)

13d

AAML1031: Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (clinicaltrials.gov)

P3, N=1645, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Sep 2027 --> Mar 2026

13 days ago

Trial completion • Trial completion date

FLT3-ITD mutation

sorafenib • cytarabine • bortezomib • etoposide IV • daunorubicin • mitoxantrone • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)

19d

AALL0932: Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma (clinicaltrials.gov)

P3, N=9350, Completed, Children's Oncology Group | Active, not recruiting --> Completed

19 days ago

Trial completion

cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)

19d

MM1YA-A04: Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) (clinicaltrials.gov)

P2, N=162, Recruiting, National Cancer Institute (NCI) | Not yet recruiting --> Recruiting

19 days ago

Enrollment open

ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • RUNX1T1 (RUNX1 Partner Transcriptional Co-Repressor 1)

Venclexta (venetoclax) • cytarabine • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • Starasid (cytarabine ocfosfate)

28d

Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia (clinicaltrials.gov)

P1/2, N=53, Terminated, M.D. Anderson Cancer Center | Trial completion date: Dec 2026 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2026 --> May 2026; <75% participation

28 days ago

Trial completion date • Trial termination • Trial primary completion date

BCL2 (B-cell CLL/lymphoma 2)

Venclexta (venetoclax) • Rituxan (rituximab) • cytarabine • cyclophosphamide • methotrexate • vincristine • Oncaspar liquid (pegaspargase) • Truxima (rituximab-abbs) • nelarabine • Starasid (cytarabine ocfosfate)